TikoMed
TikoMed AB is a privately-held Swedish biotechnology company developing ILB®, a patented modified dextran sulfate drug candidate in Phase II clinical development for ALS and expanding into myocardial infarction, with EU and FDA Orphan Drug Designation.
- Company typePrivate
- Founded2002
- HeadquartersViken, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What TikoMed does
TikoMed AB is a privately-held Swedish biotechnology company founded in 2002 by the Bruce family, headquartered in Viken, Sweden, with 11–50 employees. The company develops a single drug platform asset, ILB®, a patented low molecular weight modified dextran sulfate compound discovered serendipitously. ILB® has a pleiotropic mechanism of action that stimulates endogenous release of heparin-binding growth factors (HGF, BDNF) from glypican reservoirs, downregulates neuroinflammation, and prevents fibrosis via decorin upregulation — effects that have been characterized across preclinical models of ALS, traumatic brain injury, stroke, glaucoma, limb ischemia, and viral infections (Dengue, Zika, Yellow Fever, SARS-CoV-2).
TikoMed's near-term development focus is Amyotrophic Lateral Sclerosis, where ILB® has completed Phase IIa trials at Sahlgrenska University Hospital and Queen Elizabeth Hospital Birmingham, and is now in the IMPACT Phase IIb study (120 patients, head-to-head versus riluzole) at Oslo University Hospital. The company has been granted Orphan Drug Designation by both the European Commission (2020) and the FDA for ILB® in ALS, providing 10 years of EU market exclusivity contingent on approval. In February 2026 the company signed a letter of intent with Karolinska Institutet to initiate the ILBIAMI study, ILB®'s first clinical investigation in myocardial infarction, expanding the pipeline into cardiology.
The business model is development-stage pharmaceutical: TikoMed funds clinical trials through equity and operates as an investment/holding structure developing projects through daughter companies, with explicit intent to monetize via licensing deals or trade sale to larger biopharma. Pricing is not publicly disclosed. The company is governed by a recently reconstituted Board (Göran Groth as Chairman from June 2025) and a Scientific Advisory Board of leading ALS experts (Cudkowicz, Ingre, Shefner, Chiò), with Dr. Björn Pilström appointed CEO in September 2025.
TikoMed firmographics
Firmographics- Name
- TikoMed
- Legal name
- TikoMed AB
- Website
- https://tikomed.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TikoMed AB is a privately-held Swedish biotechnology company developing ILB®, a patented modified dextran sulfate drug candidate in Phase II clinical development for ALS and expanding into myocardial infarction, with EU and FDA Orphan Drug Designation.
- Ownership category
- akta.pro rank
TikoMed industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where TikoMed is headquartered
LocationHeadquarters
- HQ city
- Viken
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
TikoMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Licensing/Partnering: TikoMed develops drug candidates through clinical stages then exits through partnering deals or trade sale to biopharmas capable of progressing candidates to market. TikoMed AB is an investment/holding company that develops projects through daughter companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
TikoMed product offering
Product offeringCore offering
TikoMed develops ILB®, a proprietary modified low-molecular-weight dextran sulfate drug platform with a pleiotropic mechanism that stimulates endogenous tissue repair by releasing growth factors (HGF, BDNF), modulating inflammatory response, and preventing fibrosis. The company advances ILB® through Phase II clinical trials primarily for amyotrophic lateral sclerosis (ALS), with expansion into myocardial infarction and other acute and chronic neurodegenerative indications. TikoMed plans to commercialize via licensing or trade-sale partnerships with larger biopharmaceutical companies.
Product overview
TikoMed is a Swedish biotechnology company that has developed ILB® as its core drug platform technology. ILB® is a modified low molecular weight dextran sulfate compound discovered serendipitously, with a broad pleiotropic mechanism of action that stimulates the body's endogenous repair systems by releasing growth factors and modulating inflammatory responses. The company's initial development programs focus on Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), islet cell transplantation, and the company is exploring additional therapeutic indications such as myocardial infarction and various fibrotic diseases. The platform technology addresses the underlying pathology of disease rather than just treating symptoms, with potential applications across both acute and chronic neurodegenerative conditions.
Differentiator
Problem solved
Functional benefit
Brands
- ILB®: A modified form of dextran sulfate - TikoMed's lead drug candidate that stimulates the body's own repair mechanisms. ILB® has demonstrated neuroprotective and regenerative effects in neurodegenerative conditions including ALS, and has shown antiviral properties against various viruses.
Products and services
- ILB® ILB® is a modified low-molecular-weight dextran sulfate drug candidate with a pleiotropic mechanism of action that stimulates the body's own repair mechanisms. It triggers release of growth factors (HGF, BDNF) bound to glypican in blood-vessel walls, downregulates inflammatory responses, prevents fibrosis via decorin upregulation, and mitigates oxidative stress, mitochondrial dysfunction, and glutamate excitotoxicity. It is administered subcutaneously for long-term treatment and is being developed primarily for amyotrophic lateral sclerosis (ALS), with additional indications in traumatic brain injury, glaucoma, stroke, myocardial infarction, and viral infections.
Quantifiable outcome
- ALS progression halted/reversed in all 13 study participants assessed using ALSFRS-R and Norris clinical rating scales in Phase II trial at Sahlgrenska
- +5 more outcomes
Companies that use TikoMed
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
TikoMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TikoMed partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Karolinska Institutet (Department of Medicine Solna)coreLetter of intent signed for ILBIAMI clinical study evaluating ILB® in limiting heart muscle damage following myocardial infarction. Karolinska Institutet will serve as study sponsor while TikoMed provides active product, placebo substance, and scientific support. Study expected to begin 2026 pending regulatory approval. First clinical investigation of ILB® in this therapeutic indication.
- University of Birmingham (D3B Team - Queen Elizabeth Hospital)coreCollaboration on Phase II clinical trial of ILB® in ALS patients at Queen Elizabeth Hospital Birmingham. Published results in PLOS ONE demonstrated safety and tolerability of long-term weekly ILB® injections in 11 ALS patients. Trial sponsored by University of Birmingham with TikoMed providing support.
- Oslo University Hospital (Division of Clinical Neuroscience)coreOfficial research collaboration agreement signed for ALS clinical studies. TikoMed completed two successful Phase 2a clinical studies in ALS with promising results. The IMPACT Phase IIb study with 120 patients commenced enrollment in 2026. Oslo University Hospital serves as study sponsor with TikoMed providing ILB® and placebo.
- Sahlgrenska University HospitalcorePhase II ALS clinical trial collaboration with Dr. Lennart Persson as principal investigator. 15 patients with ALS received ILB® for a four-week treatment period followed by a three-month follow-up period. Study established safety and tolerability profile.
- Scientific Advisory Board (Merit Cudkowicz, Caroline Ingre, Jeremy Shefner, Adriano Chiò)coreFormed in September 2023 with world-renowned ALS experts from Mass General/Harvard, Karolinska Institutet, Barrow Neurological Institute, and University of Torino. Board advises management on Phase 2 clinical development and provides scientific credibility and network access.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
TikoMed competitors and assessment
Company assessmentEmerging players
- QurAlis Corporation: Emerging clinical-stage biotech developing precision ALS therapies targeting ALS genetics and motor neuron biology. Comparable as a younger, venture-backed ALS-focused developer whose progress signals competitive dynamics and partnership M&A appetite in the ALS space.
Regional players
- Treeway B.V. Dutch clinical-stage ALS-focused biotech developing TW001 (edaravone) and other ALS programs. European regional peer with a similar small-company, indication-focused model and a useful comparator for European ALS partnering pathways.
Direct peers
- MediciNova: Clinical-stage biopharma developing ibudilast (MN-166) in ALS and other neurological conditions with anti-neuroinflammatory mechanism. Comparable to TikoMed in target indication (ALS), small-mid cap profile, and pleiotropic anti-inflammatory drug positioning.
- Cytokinetics: Clinical-stage biopharma developing reldesemtiv and tirasemtiv for ALS and other neuromuscular diseases. Directly comparable late-stage ALS drug developer with a similar specialty-pharma profile and a similar partnering/exit pathway.
- Clene Nanomedicine: Late-stage clinical developer of CNM-Au8, a gold nanocatalyst in Phase II/III trials for ALS, MS and Parkinson's. Closest direct peer in mechanism-flavor (novel neuroprotective platform) and indication focus (ALS), making it a key reference for valuation and clinical read-throughs.
- BrainStorm Cell Therapeutics: Developer of NurOwn (autologous MSC neurotrophic-factor secreting cell therapy) for ALS, with completed Phase III. Direct peer in ALS disease-modifying therapies and a useful read-through on ALS trial design, regulatory expectations, and partnership outcomes.
- AB Science: European specialty pharma developing masitinib for ALS and other inflammatory/neurodegenerative indications. Direct peer in specialty-pharma positioning, immunomodulatory mechanism, and EU-based ALS development.
- Helixmith: Clinical-stage biotech developing Engensis (VM202) gene therapy for ALS and other neurological indications. Comparable in indication, late-stage clinical status, and an example of a neuro-regenerative therapeutic competing in the same ALS opportunity set.
Broad incumbents
- Biogen: Large neuroscience biopharma with approved ALS therapy Tofersen (SOD1-ALS) and a broad neurology pipeline. Most relevant direct comparability is the Biogen/Ionis ASO platform addressing genetic ALS, a head-to-head benchmark for any ALS disease-modifying program like TikoMed's ILB®.
- Ionis Pharmaceuticals: Established antisense oligonucleotide platform company with multiple neurological programs including partnered ALS assets with Biogen. Comparable as a broader neuroscience platform with established ALS exposure, and a likely partner/acquirer profile for late-stage ALS assets like ILB®.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TikoMed social profiles
Digital presenceTikoMed compliance and trust
Trust signalCompliance1 record
TikoMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
TikoMed leadership team
Management profileNumber of profiles
Profiles12 records
TikoMed funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TikoMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TikoMed
What does TikoMed do?
TikoMed develops ILB®, a proprietary modified low-molecular-weight dextran sulfate drug platform with a pleiotropic mechanism that stimulates endogenous tissue repair by releasing growth factors (HGF, BDNF), modulating inflammatory response, and preventing fibrosis. The company advances ILB® through Phase II clinical trials primarily for amyotrophic lateral sclerosis (ALS), with expansion into myocardial infarction and other acute and chronic neurodegenerative indications. TikoMed plans to commercialize via licensing or trade-sale partnerships with larger biopharmaceutical companies.
Is TikoMed a public or private company?
TikoMed is a private company. It is classified as family owned and is currently operating.
When was TikoMed founded?
TikoMed was founded in 2002. It employs 11 to 50 people.
Where is TikoMed based?
TikoMed is headquartered in Viken, Sweden, in the Europe region.
How does TikoMed make money?
One revenue line is on record: pharmaceutical Licensing/Partnering.
Who are TikoMed's main competitors?
QurAlis Corporation is listed as an emerging player. Treeway B.V. is listed as a regional player. Direct peers are MediciNova, Cytokinetics, Clene Nanomedicine, BrainStorm Cell Therapeutics, AB Science and Helixmith. Broad incumbents are Biogen and Ionis Pharmaceuticals.
Does TikoMed have an API?
No public API is recorded for TikoMed.
What industry is TikoMed in?
TikoMed's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.